Biologic therapies in systemic lupus erythematosus
Identifieur interne : 002239 ( Main/Exploration ); précédent : 002238; suivant : 002240Biologic therapies in systemic lupus erythematosus
Auteurs : Christine B. Bernal [Philippines] ; Leonid D. Zamora [Philippines] ; Sandra V. Navarra [Philippines]Source :
- International Journal of Rheumatic Diseases [ 1756-1841 ] ; 2015-02.
Abstract
Significant progress has been made in the development of therapies for systemic lupus erythematosus (SLE). These include agents which target interferons, cytokines, T lymphocytes and co‐stimulatory molecules, B‐lymphocytes and B stimulatory molecules. The latter are of special interest having the most robust efficacy data to date, ranging from clinical experience to clinical trials, with belimumab as the first Food and Drug Administration‐approved biologic for the treatment of SLE. Given the wide disease heterogeneity, certain issues like clinical trial design and pharmacogenomics will continue to challenge drug development in SLE, there will always be a growing and compelling need for more of these drugs in order to alleviate the burden of illness in lupus patients.
Url:
DOI: 10.1111/1756-185X.12490
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000330
- to stream Istex, to step Curation: 000330
- to stream Istex, to step Checkpoint: 000214
- to stream Main, to step Merge: 002239
- to stream Main, to step Curation: 002239
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biologic therapies in systemic lupus erythematosus</title><author><name sortKey="Bernal, Christine B" sort="Bernal, Christine B" uniqKey="Bernal C" first="Christine B." last="Bernal">Christine B. Bernal</name></author><author><name sortKey="Zamora, Leonid D" sort="Zamora, Leonid D" uniqKey="Zamora L" first="Leonid D." last="Zamora">Leonid D. Zamora</name></author><author><name sortKey="Navarra, Sandra V" sort="Navarra, Sandra V" uniqKey="Navarra S" first="Sandra V." last="Navarra">Sandra V. Navarra</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FC40BCEECDBB1A139287676F3724B76236F4C7D3</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1111/1756-185X.12490</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-H318KP9P-G/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000330</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000330</idno><idno type="wicri:Area/Istex/Curation">000330</idno><idno type="wicri:Area/Istex/Checkpoint">000214</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000214</idno><idno type="wicri:doubleKey">1756-1841:2015:Bernal C:biologic:therapies:in</idno><idno type="wicri:Area/Main/Merge">002239</idno><idno type="wicri:Area/Main/Curation">002239</idno><idno type="wicri:Area/Main/Exploration">002239</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Biologic therapies in systemic lupus erythematosus</title><author><name sortKey="Bernal, Christine B" sort="Bernal, Christine B" uniqKey="Bernal C" first="Christine B." last="Bernal">Christine B. Bernal</name><affiliation wicri:level="1"><country xml:lang="fr">Philippines</country><wicri:regionArea>University of Santo Tomas, Manila</wicri:regionArea><wicri:noRegion>Manila</wicri:noRegion></affiliation></author><author><name sortKey="Zamora, Leonid D" sort="Zamora, Leonid D" uniqKey="Zamora L" first="Leonid D." last="Zamora">Leonid D. Zamora</name><affiliation wicri:level="1"><country xml:lang="fr">Philippines</country><wicri:regionArea>University of Santo Tomas, Manila</wicri:regionArea><wicri:noRegion>Manila</wicri:noRegion></affiliation></author><author><name sortKey="Navarra, Sandra V" sort="Navarra, Sandra V" uniqKey="Navarra S" first="Sandra V." last="Navarra">Sandra V. Navarra</name><affiliation wicri:level="1"><country xml:lang="fr">Philippines</country><wicri:regionArea>University of Santo Tomas, Manila</wicri:regionArea><wicri:noRegion>Manila</wicri:noRegion></affiliation><affiliation></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">International Journal of Rheumatic Diseases</title><title level="j" type="sub">Special issue on LUPUS in the Asia‐Pacific region</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES</title><idno type="ISSN">1756-1841</idno><idno type="eISSN">1756-185X</idno><imprint><biblScope unit="vol">18</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="146">146</biblScope><biblScope unit="page" to="153">153</biblScope><biblScope unit="page-count">8</biblScope><date type="published" when="2015-02">2015-02</date></imprint><idno type="ISSN">1756-1841</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1756-1841</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Significant progress has been made in the development of therapies for systemic lupus erythematosus (SLE). These include agents which target interferons, cytokines, T lymphocytes and co‐stimulatory molecules, B‐lymphocytes and B stimulatory molecules. The latter are of special interest having the most robust efficacy data to date, ranging from clinical experience to clinical trials, with belimumab as the first Food and Drug Administration‐approved biologic for the treatment of SLE. Given the wide disease heterogeneity, certain issues like clinical trial design and pharmacogenomics will continue to challenge drug development in SLE, there will always be a growing and compelling need for more of these drugs in order to alleviate the burden of illness in lupus patients.</div></front></TEI><affiliations><list><country><li>Philippines</li></country></list><tree><country name="Philippines"><noRegion><name sortKey="Bernal, Christine B" sort="Bernal, Christine B" uniqKey="Bernal C" first="Christine B." last="Bernal">Christine B. Bernal</name></noRegion><name sortKey="Navarra, Sandra V" sort="Navarra, Sandra V" uniqKey="Navarra S" first="Sandra V." last="Navarra">Sandra V. Navarra</name><name sortKey="Zamora, Leonid D" sort="Zamora, Leonid D" uniqKey="Zamora L" first="Leonid D." last="Zamora">Leonid D. Zamora</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002239 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002239 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FC40BCEECDBB1A139287676F3724B76236F4C7D3
|texte= Biologic therapies in systemic lupus erythematosus
}}
| This area was generated with Dilib version V0.6.34. |  |